Search the Newsreel

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SEC Filing (Aug 6, 2026)

This article details an SEC Form 144 filing by CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) on August 6, 2026. The filing indicates a proposed sale of 4,179 shares of common stock acquired through a stock option exercise, with an aggregate market value of $1,086,540, …

Charles River Laboratories International Q2 Earnings Call Highlights

Charles River Laboratories International (CRL) exceeded Q2 expectations, driven by improved demand in its Discovery and Safety Assessment (DSA) business and strong manufacturing performance. The company raised its full-year guidance for revenue, earnings, and free cash flow, anticipating a gradual recovery in biopharmaceutical demand. …

FMR LLC reports 8.8% ownership of Charles River (CRL) common stock

FMR LLC has disclosed an 8.8% beneficial ownership stake in Charles River Laboratories International, Inc. (CRL) common stock as of June 30, 2026. This translates to 4,239,751.47 shares, with FMR LLC exercising sole voting power over 4,190,715.80 shares and sole dispositive power over all …

Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More

This article details Thursday's top Wall Street analyst research calls, including upgrades, downgrades, and new initiations for various companies like Charles River Laboratories, Global Payments, AppLovin, and HubSpot. It also provides a snapshot of the market on Wednesday, noting mixed futures, a strong Dow …

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 2026: Revenue $1B, EPS ($0.03) — 10-Q Summary

Charles River Laboratories International, Inc. reported Q3 2026 results, with revenue of $1 billion and a diluted EPS loss of ($0.03), reflecting a 2.7% year-over-year decline in revenue and a significant drop in net income. The company is implementing cost-saving measures and restructuring actions …

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : BAIRD RAISES TARGET PRICE TO $291 FROM $255

Baird has increased its target price for Charles River Laboratories International, Inc. (CRL.N) from $255 to $291. This update reflects a positive outlook from the analytical firm regarding the company's financial prospects. The news was reported by Reuters.

Charles River Laboratories International, Inc. reports results for the quarter ended June 30 - Earnings Summary

Charles River Laboratories International, Inc. has released its earnings summary for the quarter that concluded on June 30. The article, sourced from Reuters, provides a brief announcement of these results. Readers can access the full report and more news on TradingView.

Charles River Laboratories International (NYSE:CRL) Posts Earnings Results, Beats Expectations By $0.28 EPS

CRL (CRL) insider files Form 144 for potential 5,046-share sale

An insider at Charles River Laboratories International, Inc. (CRL) has filed a Form 144, indicating a potential sale of up to 5,046 common shares on the NYSE, with an aggregate market value of $1,327,098.00. The shares, which represent a small portion of the 47,738,872 …

Charles River Laboratories Stock Rallies As Analysts Hike Targets

Charles River Laboratories International Inc. (NYSE: CRL) stock rallied by 10.96% following positive institutional demand and analyst upgrades, with several major banks raising their price targets. The company's Q2 2026 earnings release, set for August 5, 2026, is a key near-term catalyst, with traders …

Charles River Laboratories International Up Nearly 12%, on Track for Highest Close Since April 2024 -- Data Talk

Charles River Laboratories International (CRL) is experiencing a significant surge, with its stock up nearly 12% and on track for its highest close since April 1, 2024. The company's stock is currently trading at $262.05, marking a 31.37% increase year-to-date and making it the …

Charles River Laboratories stock hits 52-week high at $266.00 By Investing.com

Charles River Laboratories International Inc. (CRL) stock reached a new 52-week high of $266.00, surpassing its previous high of $242.73, and now boasts a market capitalization of $11.28 billion. This surge reflects a 39.78% price return over the past year and a 27.45% gain …

Charles River Laboratories International, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:CRL) 2026-08-05

Charles River Laboratories International (CRL) exceeded Q2 expectations, driven by improved demand in its Discovery and Safety Assessment (DSA) business and strong manufacturing performance. The company raised its full-year guidance for revenue, earnings, and free cash flow, anticipating a gradual recovery in biopharmaceutical demand. …

Charles River (CRL) Stock Jumps As Margin Repair Meets Valuation Doubt

Charles River Laboratories International (CRL) saw its stock jump 11.4% after Q2 non-GAAP earnings led to lifted full-year guidance, driven by portfolio cleanup and improved margins. While bulls see a clear path to margin-led repair despite flat organic revenue, bears remain concerned about structural …

(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $11.15 - $11.45, vs. FactSet Est of $11.11

Charles River Laboratories (CRL) has released its adjusted EPS guidance for 2026, projecting a range of $11.15 to $11.45. This forecast surpasses the FactSet estimate of $11.11. The announcement was made on August 5, 2026, and follows recent updates to the company's earnings guidance …

CRL: 2Q26 organic revenue and EPS beat outlook, prompting raised 2026 guidance and margin expansion

Charles River Laboratories (CRL) reported strong Q2 2026 results, with organic revenue and non-GAAP EPS surpassing expectations due to increased demand in DSA and improved Manufacturing performance. This led to a raised 2026 guidance, supported by strategic divestitures and technology investments aimed at enhancing …

Charles River Labs (NYSE: CRL) swings to Q2 loss but raises 2026 guidance

Charles River Laboratories International, Inc. (NYSE: CRL) reported a Q2 2026 revenue of $1.00 billion, a 2.7% decrease year-over-year, and swung to a GAAP net loss of $(1.5) million, or $(0.03) per share, primarily due to divestiture losses. Despite the loss, the company raised …

[10-Q] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Quarterly Earnings Report

Has Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year?

Charles River Stock Hits 52-Week High - Here's Why - Charles River (NYSE:CRL)

Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates

Charles River Laboratories’s (NYSE:CRL) Q2 CY2026 Sales Top Estimates, Stock Soars

Charles River Laboratories International Inc. stock rises Tuesday, still underperforms market

Shares of Charles River Laboratories International Inc. (CRL) rose 1.41% on Tuesday, closing at $234.12. This increase broke a four-day losing streak for the company's stock. Despite the rise, the stock still underperformed the broader market, with the S&P 500 Index and Dow Jones …

Charles River Laboratories Earnings: What To Look For From CRL

Charles River Prepares to Report Q2 Earnings: What's in Store?

Charles River Laboratories International, Inc. (CRL) is set to announce its second-quarter 2026 earnings on August 5th, with analysts forecasting a revenue decline of 5.9% and an EPS decrease of 12.8%. The company’s Research Models and Services (RMS) and Discovery and Safety Assessment (DSA) …

Charles River Laboratories International Inc (CRL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Charles River Laboratories International Inc (CRL), noting its current valuation score and ranking within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio, comparing it to recent highs and lows, but states that …

Charles River Laboratories International Inc. Stock Rises 7.2%, Outperforms Peers

Shares of Charles River Laboratories International Inc. (CRL) experienced a significant rise of 7.2% on Wednesday, outperforming its competitors. This strong performance indicates a positive market reaction to the company's recent activities or broader sector trends.

Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors

Charles River Laboratories International Inc. (CRL) stock dropped 2.34% on Wednesday, closing at $234.80. This underperformance occurred on a generally poor trading day where both the S&P 500 and Dow Jones Industrial Average also saw significant declines. The company's shares finished 3.27% below its …

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Charles River Laboratories International Jumps 6.0% in Broad Rally

Charles River Laboratories International, Inc. saw its stock surge 6.0% on Tuesday, outperforming its sector peers in a broad market rally. This strong performance, which suggests investor confidence in the company within the diagnostics and research space, is attributed to a sector-wide phenomenon rather …

Charles River Labs /US Number of Employees 2026 | Employee Count & Headcount Data

Charles River Laboratories International, Inc. (CRL) had approximately 19,566 employees worldwide as of March 2026, marking a 12.8% decline since 2023. Despite this, the company is actively hiring, with 885 job postings in 2026. The workforce is concentrated in the United States, and the …

Charles River Laboratories International Inc (CRL) Technical Analysis: Support, Resistance, Indicators & Moving Averages — TradingKey

This article provides a technical analysis of Charles River Laboratories International Inc (CRL), detailing its current price momentum score, support and resistance levels. It further breaks down various technical indicators and moving averages, offering insights into potential trading signals and the stock's volatility. The …

CRL - A Company Preparing for the Future: Charles River Laboratories

Charles River Laboratories (CRL) recently acquired K.F. (Cambodia) Ltd., a non-human primate (NHP) supplier, for $510 million. This acquisition is crucial because NHPs are essential for preclinical drug testing, and the global supply has been constrained due to Chinese export restrictions and slow primate …

CRL|Charles River Laboratories International Inc|Price:226.580|Chg%:-2.740

This article provides an overview of Charles River Laboratories International Inc (CRL), a drug development company. It details the company's business segments, key financial figures, executive team, and major shareholders. The article also touches upon institutional shareholding and the primary revenue source for the …

ETFs Investing in Charles River Laboratories International, Inc. Stocks

This article lists various ETFs that include Charles River Laboratories International, Inc. (RV6) stocks in their portfolios, offering investors diversified exposure to the company. The ETFs are sorted by market value and provide details such as issuer, management style, expense ratio, AUM, price change, …